PDF(Pubmed)
Abstract：
UNASSIGNED: To determine the relationship between Gly64Asp (rs77630697) polymorphism of multidrug and toxin extrusion-1 (MATE-1) and therapeutic response of metformin in Type-2 diabetic patients.
UNASSIGNED: A longitudinal study was conducted at Riphah International Hospital, Islamabad from June 2020 to December 2021. Type-2 diabetic patients (n=200) on metformin monotherapy fulfilling the inclusion criteria were enrolled and followed up till three months. Based on change in HbA1c, they were divided into responders and non-responders. DNA was extracted and genotyping was done by TETRA ARMS PCR. Data was entered and association was analyzed by SPSS 22.
UNASSIGNED: Out of 200 participants, 104 were categorized as responders and 96 as non-responders. The genotype and allelic distribution of rs77630697 was significantly different between responders and non-responders. The variant genotype (GG) was most prevalent among the study population and among responders. After follow up of three months, difference in glycemic response was found to be statistically significant (p < 0.05) among three genotypes (GG, GA and AA). The decline in HbA1c was highest in GG genotype with almost two-fold reduction in comparison with GA and AA. Carriers of allele A were significantly associated with impaired response to metformin.
UNASSIGNED: The variable therapeutic response to metformin in the responders and non-responders may be contributed to rs77630697 isoform variation of MATE-1.
UNASSIGNED: A longitudinal study was conducted at Riphah International Hospital, Islamabad from June 2020 to December 2021. Type-2 diabetic patients (n=200) on metformin monotherapy fulfilling the inclusion criteria were enrolled and followed up till three months. Based on change in HbA1c, they were divided into responders and non-responders. DNA was extracted and genotyping was done by TETRA ARMS PCR. Data was entered and association was analyzed by SPSS 22.
UNASSIGNED: Out of 200 participants, 104 were categorized as responders and 96 as non-responders. The genotype and allelic distribution of rs77630697 was significantly different between responders and non-responders. The variant genotype (GG) was most prevalent among the study population and among responders. After follow up of three months, difference in glycemic response was found to be statistically significant (p < 0.05) among three genotypes (GG, GA and AA). The decline in HbA1c was highest in GG genotype with almost two-fold reduction in comparison with GA and AA. Carriers of allele A were significantly associated with impaired response to metformin.
UNASSIGNED: The variable therapeutic response to metformin in the responders and non-responders may be contributed to rs77630697 isoform variation of MATE-1.
摘要：
■确定Gly64Asp（rs77630697）多药和毒素挤出-1（MATE-1）的多态性与2型糖尿病患者二甲双胍治疗反应之间的关系。
■在Riphah国际医院进行了一项纵向研究，2020年6月至2021年12月，伊斯兰堡。纳入符合纳入标准的二甲双胍单药治疗的2型糖尿病患者（n=200），并随访至三个月。基于HbA1c的变化，他们分为响应者和非响应者。提取DNA并通过TETRAARMSPCR进行基因分型。输入数据并通过SPSS22进行关联分析。
■在200名参与者中，104人被归类为响应者，96人被归类为非响应者。rs77630697的基因型和等位基因分布在应答者和非应答者之间显著不同。变异基因型（GG）在研究人群和应答者中最普遍。经过三个月的随访,在三种基因型（GG，GA和AA）。与GA和AA相比，GG基因型的HbA1c下降幅度最大，几乎减少了两倍。等位基因A的携带者与二甲双胍反应受损显著相关。
■应答者和非应答者对二甲双胍的可变治疗反应可能与MATE-1的rs77630697同工型变异有关。
■在Riphah国际医院进行了一项纵向研究，2020年6月至2021年12月，伊斯兰堡。纳入符合纳入标准的二甲双胍单药治疗的2型糖尿病患者（n=200），并随访至三个月。基于HbA1c的变化，他们分为响应者和非响应者。提取DNA并通过TETRAARMSPCR进行基因分型。输入数据并通过SPSS22进行关联分析。
■在200名参与者中，104人被归类为响应者，96人被归类为非响应者。rs77630697的基因型和等位基因分布在应答者和非应答者之间显著不同。变异基因型（GG）在研究人群和应答者中最普遍。经过三个月的随访,在三种基因型（GG，GA和AA）。与GA和AA相比，GG基因型的HbA1c下降幅度最大，几乎减少了两倍。等位基因A的携带者与二甲双胍反应受损显著相关。
■应答者和非应答者对二甲双胍的可变治疗反应可能与MATE-1的rs77630697同工型变异有关。
